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Ostenil mini) and triamcinolone (TA; Volon A10) for treatment
of osteoarthritis (OA) of the carpometacarpal (CMC) joint of the
thumb in a 26-week, controlled, randomized, masked-observer
study.
Methods: Patients were treated with three intra-articular injec-
tions of either SH (n=28) or TA (n=28). Primary assessments
were pain according to VAS and extensive clinical and func-
tional parameters such as swelling, grip power and range of
motion. The population was analysed using one- and two-sided
Mann-Whitney (MW) estimators.
Results: Maximum pain relief occurred at 2-3 weeks for TA and
at week 26 for SH after the first intra-articular injection. At weeks
2-3 TA was significantly better than SH (MW: 0.3319 and 0.3063;
p=0.9827 and 0.9929). At week 26 a slight superiority of SH could
be observed (MW: 0.53; p=0.3624) and non-inferiority could be
proven. After 26 weeks lateral pinch power was significantly
better in the SH-group (MW: 0.6331; p=0.0226). In all, 88.0% of
patients treated with SH and 79.2% of the TA-group described
pain improvement after 26 weeks. No adverse events with causal
connection to the investigational products occurred.
Conclusions: We conclude that a single course of three SH in-
jections is effective in relieving pain and improving joint function in
patients with OA of the CMC joint of the thumb. Although in com-
parison with triamcinolone its effects are achieved more slowly,
the results indicate a superior long-lasting effect of hyaluronan at
6 months after end of treatment period.
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SUPPRESSION OF TNF-α, IL-1β, INOS, AND P38
EXPRESSION BY THE COMBINATION OF AVOCADO SOY
UNSAPONIFIABLES, GLUCOSAMINE, AND CHONDROITIN
SULFATE IN HUMAN MACROPHAGE-LIKE THP-1 CELLS
R.Y. Au, A.Y. Au, C.G. Frondoza
Nutramax Laboratories, Inc., Edgewood, MD
Purpose: The present study determines whether the combina-
tion of Avocado Soy Unsaponifiables (ASU), glucosamine (Glu),
and chondroitin sulfate (CS) was more effective in suppressing
pro-inflammatory gene expression than ASU alone, or Glu and
CS together.
Methods: Human monocyte/macrophage surrogate THP-1 cells
(5 x 105 cells) were incubated for 24 hrs at 37°C and 5% CO2
with: (i) control media alone, (ii) ASU (8.3 μg/ml; NMX1000TM-
ASU), (iii) Glu (15 mM; FCHG49®) and CS (20 μg/ml; TRH122®),
or with (iv) a combination of ASU (8.3 μg/ml), Glu (15mM), and
CS (20 μg/ml). All test materials were supplied by Nutramax
Laboratories, Inc., Edgewood, MD. The cells were then activated
with 20 ng/ml LPS for 1 hour. Total RNA was extracted and
subjected to RT-PCR analysis using primers specific to TNF-α,
IL-1β, iNOS, p38, and S14 as the housekeeping gene.
Results: Pre-treatment with the combination of ASU, Glu, and
CS profoundly suppressed the expression of TNF-α, IL-1β, and
iNOS by 50-80% in activated THP-1 cells. The combination
treatment reduced TNF-α and IL-1β expression to levels similar
to baseline non-activated controls and reduced iNOS expression
to levels lower than baseline non-activated levels. The inhibitory
effect of the combined preparation on TNF-α, IL-1β, and iNOS
expression is more profound than ASU alone, or Glu and CS
together. The inhibition of cytokine and iNOS expression is
associated with a profound suppression of p38 expression.
Conclusions: In the present study, we demonstrate that the
combination of ASU, Glu, and CS was more effective in sup-
pressing pro-inflammatory gene expression than ASU alone, or
Glu and CS together. The combined preparation suppressed
TNF-α, IL-1β, and iNOS expression by downregulating p38, a
key signal transduction molecule involved in inflammation. Our
present findings suggest the utility of the combination product
to alleviate pain and inflammation in OA patients who may not
clinically respond to Glu and CS alone.
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EFFECTS OF HEAT STIMULATION VIA MICROWAVE
APPLICATOR ON CARTILAGE METABOLISM AND HSP70
EXPRESSION IN RABBIT KNEE JOINT
K.A. Takahashi, H. Tonomura, Y. Arai, A. Inoue, K. Sakao,
M. Saito, T. Kubo
Graduate School of Medical Science, Kyoto Prefectural
University of Medicine, Kyoto, Japan
Purpose: Thermotherapy is widely used to conservatively treat
joint diseases such as osteoarthritis (OA). While heat stimulation
of joints increases pain threshold to alleviate pain, its effects
on the articular cartilage have not been clarified. In the present
study, heat stimulation was applied to rabbit knee joints to in-
vestigate the changes in expressions of heat shock protein 70
(HSP70) and cartilage matrix genes in the articular cartilage in
vivo.
Methods: Heat stimulation (0-80 W) was applied to the knee
joints of Japanese white rabbits for 20 min using a microwave
applicator (2.45-GHz). After 8-72 hrs, the articular cartilage was
removed from the knee joints and proteins and total RNA were
extracted. As controls, the knee joints without heat stimulation
were analyzed. Expression of HSP70 was confirmed by real-
time PCR and Western blotting. Expression of proteoglycan core
protein and type II collagen were quantified using real-time PCR
to assess cartilage matrix metabolism.
Results: Compared to controls, expression of HSP70 mRNA was
higher with not less than 40 W of heat stimulation in an intensity-
dependent manner. Expressions of proteoglycan core protein
and type II collagen mRNA were higher with not less than 20 W
of heat stimulation and peaked with 40 W. When quercetin was
used to block the increases in HSP70 expression, the expression
of proteoglycan core protein mRNA did not increase.
Conclusions: External heat stimulation increased expression of
HSP70 in the articular cartilage. This suggested that external
heat stimulation reached the articular cartilage. Heat stimulation
also increased expression of proteoglycan core protein and type
II collagen mRNA in the articular cartilage, indicating increased
cartilage metabolism. HSP70 might thus be involved in the in-
creased expression of proteoglycan core protein. With some
improvements, heat stimulation might be actively used to protect
the cartilage in OA.
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THE EFFICACY AND SAFETY OF CRX-102 - A NOVEL
SYNCRETIC DRUG CANDIDATE - IN HAND
OSTEOARTHRITIS (HOA): RESULTS FROM A PLACEBO-
CONTROLLED RANDOMIZED CLINICAL TRIAL (RCT)
T.K. Kvien1, B. Slatkowsky-Christensen1, E. Fjeld2, A. Prøven2,
Ø. Palm3, K. Mikkelsen4, J. Anderson5, Y. Zhang5, M. Nichols5,
J. Lessem5
1Diakonhjemmet Hospital, Oslo, Norway, 2Martina Hansens
Hospital, Sandvika, Norway, 3Dept. of Rheumatology, Østfold
Hospital, Sarpsborg, Norway, 4Lillehammer Hospital for
Rheumatic Diseases, Lillehammer, Norway, 5CombinatoRx Inc,
Cambridge, MA
Purpose: A syncretic drug comprises two compounds that are
designed to act synergistically through multiple pathways to pro-
vide a novel therapeutic effect, which neither component can
achieve alone. The syncretic drug candidate CRx-102 comprises
dipyramidole and low dose prednisolone and is in clinical de-
